Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885782 | 0.81 | LMNA (0.45) | EGFRLMNACA12CA1CA2 | |
| SCHEMBL6885666 | 0.81 | LMNA (0.31) | LMNAMAPK1GAA | |
| SCHEMBL6868584 | 0.81 | TYMS (0.39) | EGFRLMNACA12CA1CA2 | |
| SCHEMBL6866412 | 0.80 | TYMS (0.38) | EGFRLMNACA12CA1CA2 | |
| SCHEMBL6871110 | 0.80 | TYMS (0.38) | EGFRLMNACA12CA1CA2 | |
| SCHEMBL6869711 | 0.79 | TYMS (0.37) | EGFRLMNACA12CA1CA2 | |
| SCHEMBL6887016 | 0.78 | LMNA (0.45) | EGFRLMNACA12CA1CA2 | |
| SCHEMBL6869123 | 0.77 | LMNA (0.40) | EGFRLMNACA12CA1CA2 | |
| SCHEMBL6871145 | 0.74 | TYMS (0.40) | EGFRLMNACA12CA1CA2 | |
| SCHEMBL6862014 | 0.74 | TYMS (0.40) | EGFRLMNACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040158066-A1 | Novel pyridylmethylaminopyrimidines | ALTANA PHARMA AG (DE) | 2004-08-12 | — | — | US | disclosed |
| EP-1395592-A1 | NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES | ALTANA Pharma AG (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094831-A1 | NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158066-A1 | Novel pyridylmethylaminopyrimidines | PGLS, PLPBP, PDXK | EGFR 1662/4885LMNA 4589/4885CA12 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.